Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290926 | 0.84 | APP (0.72) | APPKDM4ERAB9AALDH1A1GAA | |
| SCHEMBL2536926 | 0.84 | APP (0.72) | APPKDM4ERAB9AALDH1A1GLA | |
| SCHEMBL14076026 | 0.83 | APP (0.71) | APPKDM4ERAB9AMAPTSMN1; SMN2 | |
| SCHEMBL15095457 | 0.82 | APP (0.69) | APPKDM4ERAB9AMAPTSMN1; SMN2 | |
| SCHEMBL913956 | 0.74 | APP (1.00) | APP | |
| SCHEMBL14067489 | 0.74 | APP (0.58) | APP | |
| SCHEMBL17626879 | 0.74 | APP (0.58) | APPKDM4ERAB9AALDH1A1GAA | |
| SCHEMBL14076031 | 0.71 | APP (0.74) | APPKDM4ERAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL7508553 | 0.69 | RAB9A (0.62) | APPKDM4ERAB9AALDH1A1GLA | |
| SCHEMBL16212916 | 0.69 | TLR9 (0.81) | APPKDM4ERAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2021340-A2 | BETA-AMYLOID PET IMAGING AGENTS | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007124345-A2 | BETA-AMYLOID PET IMAGING AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124345-A2 | BETA-AMYLOID PET IMAGING AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | APP 1/4885KDM4E 3812/4885RAB9A 3988/4885 |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | APP 1/4885KDM4E 3812/4885RAB9A 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.